+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application - Global Forecast 2025-2030- Product Image
Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application - Global Forecast 2025-2030- Product Image
Sale

Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5925178
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neoantigen Cancer Vaccine Market grew from USD 57.14 million in 2023 to USD 60.44 million in 2024. It is expected to continue growing at a CAGR of 5.17%, reaching USD 81.35 million by 2030.

The neoantigen cancer vaccine market focuses on personalized immunotherapy treatments tailored to patient-specific neoantigens, which are unique mutations in tumor cells. These vaccines aim to stimulate the immune system to target and destroy cancerous cells, marking a significant advancement in oncology. This approach is crucial due to its potential to improve survival rates and reduce relapse, given its personalized nature. Applications extend from solid to hematologic malignancies, with end-users including hospitals, clinics, and research institutions. Market growth is driven by increasing cancer prevalence, advancements in genomics and biotechnology, and a strong R&D pipeline. Global collaborations and strategic partnerships further fuel advancements by leveraging shared expertise and resources.

Latest opportunities arise from technological innovations enabling faster and more accurate neoantigen identification, thus streamlining vaccine development. Additionally, regulatory bodies' evolving frameworks aimed at expediting approval processes provide a supportive environment for trial and commercialization. However, challenges persist, including high costs of development, complex manufacturing processes, and variability in patient response due to genetic differences. Stringent regulatory requirements also pose a barrier, potentially delaying market entry and impacting profitability. To overcome these limitations, investing in AI and bioinformatics can enhance neoantigen prediction accuracy, while breakthroughs in CRISPR and gene editing hold promise for improving vaccine efficacy.

Innovation areas include advancements in delivery mechanisms, such as nanoparticle-based systems, which might improve immune response efficacy and patient tolerability. Future research should emphasize biomarker identification to predict patient response better and guide personalized treatment plans. The market's dynamic nature, characterized by rapid technological change and heightened competition, necessitates continuous innovation and adaptation. By prioritizing cross-industry collaborations and engaging in multi-center clinical trials, businesses can position themselves strategically to capitalize on emerging trends, ensuring sustained growth and a competitive edge in the evolving neoantigen cancer vaccine landscape.

Understanding Market Dynamics in the Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of cancer globally
    • Improvements in genomic sequencing and immunotherapy
    • Inclination towards early diagnosis and treatment of cancer
  • Market Restraints
    • High cost and complexity in manufacturing
  • Market Opportunities
    • Ongoing R&D to improve efficacy of neoantigen cancer vaccine
    • Emerging development of combination therapies
  • Market Challenges
    • Adverse effects and ethical issues

Exploring Porter’s Five Forces for the Neoantigen Cancer Vaccine Market

Porter’s Five Forces framework further strengthens the insights of the Neoantigen Cancer Vaccine Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Neoantigen Cancer Vaccine Market

External macro-environmental factors deeply influence the performance of the Neoantigen Cancer Vaccine Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neoantigen Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include ", "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc., Advaxis Inc., Agenus Inc., AstraZeneca plc, Avidea Technologies, BioLineRx, BioNTech SE, Brightpath Biotherapeutics Co., Ltd., CureVac N.V., Elicio Therapeutics Inc, F. Hoffmann-La Roche Ltd., Genocea Biosciences Inc, Gilead Sciences, Inc., Gritstone bio, Inc., Immunomic Therapeutics, Inc., IMV Inc, ISA Pharmaceuticals BV, Medigene AG, Merck & Co., Inc., Neophore Limited, Nouscom, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis srl.

Market Segmentation & Coverage

This research report categorizes the Neoantigen Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Off-The Shell Neoantigen Vaccine
    • Personalized Neo-Antigen Vaccine
  • Technology
    • HLA Typing
    • RNA Sequencing
    • Whole Genome Sequencing
  • Delivery Mechanism
    • Electroporation
    • Gene Gun
    • Liposomes
    • Virosomes
  • Neoantigen Type
    • Dendritic Cell
    • Nucleic Acid
    • Synthetic Long Peptide
    • Tumor Cell
  • Route of Administration
    • Intramuscular
    • Intravenous
    • Transdermal
  • Application
    • Brain Cancer
    • Gastrointestinal Cancer
    • Lung Cancer
    • Melanoma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer globally
5.1.1.2. Improvements in genomic sequencing and immunotherapy
5.1.1.3. Inclination towards early diagnosis and treatment of cancer
5.1.2. Restraints
5.1.2.1. High cost and complexity in manufacturing
5.1.3. Opportunities
5.1.3.1. Ongoing R&D to improve efficacy of neoantigen cancer vaccine
5.1.3.2. Emerging development of combination therapies
5.1.4. Challenges
5.1.4.1. Adverse effects and ethical issues
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Neoantigen Cancer Vaccine Market, by Product
6.1. Introduction
6.2. Off-The Shell Neoantigen Vaccine
6.3. Personalized Neo-Antigen Vaccine
7. Neoantigen Cancer Vaccine Market, by Technology
7.1. Introduction
7.2. HLA Typing
7.3. RNA Sequencing
7.4. Whole Genome Sequencing
8. Neoantigen Cancer Vaccine Market, by Delivery Mechanism
8.1. Introduction
8.2. Electroporation
8.3. Gene Gun
8.4. Liposomes
8.5. Virosomes
9. Neoantigen Cancer Vaccine Market, by Neoantigen Type
9.1. Introduction
9.2. Dendritic Cell
9.3. Nucleic Acid
9.4. Synthetic Long Peptide
9.5. Tumor Cell
10. Neoantigen Cancer Vaccine Market, by Route of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Transdermal
11. Neoantigen Cancer Vaccine Market, by Application
11.1. Introduction
11.2. Brain Cancer
11.3. Gastrointestinal Cancer
11.4. Lung Cancer
11.5. Melanoma
12. Americas Neoantigen Cancer Vaccine Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Neoantigen Cancer Vaccine Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
FIGURE 2. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2030 (%)
FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NEOANTIGEN CANCER VACCINE MARKET DYNAMICS
TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY OFF-THE SHELL NEOANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEO-ANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VIROSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NUCLEIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC LONG PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GASTROINTESTINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 53. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 55. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 61. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 85. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 87. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 88. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 92. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 93. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 94. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 103. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 105. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 106. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 139. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 141. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 142. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 157. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 158. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 160. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 161. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 164. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 166. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 167. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 170. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 172. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 173. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 176. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 178. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 182. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 183. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 184. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 194. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 196. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 197. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 212. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 214. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 215. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 218. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 220. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 221. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 224. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 226. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 227. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 248. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 250. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 251. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 266. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 268. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 269. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
TABLE 284. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Neoantigen Cancer Vaccine Market, which are profiled in this report, include:
  • "
  • "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • Advaxis Inc.
  • Agenus Inc.
  • AstraZeneca plc
  • Avidea Technologies
  • BioLineRx
  • BioNTech SE
  • Brightpath Biotherapeutics Co., Ltd.
  • CureVac N.V.
  • Elicio Therapeutics Inc
  • F. Hoffmann-La Roche Ltd.
  • Genocea Biosciences Inc
  • Gilead Sciences, Inc.
  • Gritstone bio, Inc.
  • Immunomic Therapeutics, Inc.
  • IMV Inc
  • ISA Pharmaceuticals BV
  • Medigene AG
  • Merck & Co., Inc.
  • Neophore Limited
  • Nouscom
  • Nykode Therapeutics ASA
  • OSE Immunotherapeutics
  • Takis srl

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 60.44 Million
Forecasted Market Value ( USD ) by 2030 $ 81.35 Million
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Neoantigen Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Neoantigen Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Neoantigen-based Personalized Cancer therapeutic Vaccines - Pipeline Insight, 2024 - Product Image

Neoantigen-based Personalized Cancer therapeutic Vaccines - Pipeline Insight, 2024

  • Drug Pipelines
  • 50 Pages
  • Global
From
Personalized Cancer Vaccines Market 2024 - Product Image

Personalized Cancer Vaccines Market 2024

  • Report
  • 175 Pages
  • Global
From
Dendritic Cell Cancer Vaccine Market by Cancer Type, End-use - Global Forecast 2025-2030 - Product Image

Dendritic Cell Cancer Vaccine Market by Cancer Type, End-use - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Cancer Vaccines Market by Technology, Treatment Method, Application - Global Forecast 2025-2030 - Product Image

Cancer Vaccines Market by Technology, Treatment Method, Application - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From

About the Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine market is a subset of the larger Cancer Vaccine market. Neoantigen Cancer Vaccines are a type of personalized cancer immunotherapy that uses a patient’s own tumor-specific mutations to create a vaccine tailored to their individual cancer. These vaccines are designed to stimulate the patient’s immune system to recognize and attack cancer cells. Neoantigen Cancer Vaccines are still in the early stages of development, but have shown promise in clinical trials. The Neoantigen Cancer Vaccine market is expected to grow as more personalized cancer treatments become available. Companies in the market include Moderna, BioNTech, CureVac, and Inovio Pharmaceuticals. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.